Customize
Quick Links
Specialties

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. These activites are not approved for AMA PRA Category 1 Credit

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie; Ariad Pharmaceuticals, Inc; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc; Bristol-Myers Squibb; Genentech; Lilly; Merck Sharp & Dohme Corp; Novartis Pharmaceuticals Corporation; and Takeda Oncology.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Community Practice Connections™: 4th Annual Miami Lung Cancer Conference® PER Pulse™ Recap

PER Pulse Recap

PER Pulse™ Recap


1 of 3
PER Pulse™ Recap

Updates on First-Line Therapy in EGFR Mutation-Positive NSCLC

The 4th Annual Miami Lung Cancer Conference™, which was held on April 8, 2017, featured internationally recognized experts in thoracic malignancies. These experts, along with representatives from community practice, discussed key advances in the treatment of patients with lung cancer. This first of 3 PER Pulse™ Recaps from the Miami Lung Cancer Conference focuses on recent data comparing tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR).

Currently, erlotinib, gefitinib, and afatinib are approved as first-line therapy for patients with non–small cell lung cancer (NSCLC) and mutations in the EGFR gene. Until the randomized phase II LUX-Lung 7 trial, data on direct comparisons between these agents were lacking (Table). Subsequently, the phase III ARCHER 1050 compared the second-generation EGFR TKI dacomitinib to gefitinib; this trial excluded patients with brain metastases; however. Finally, the phase III FLAURA trial compared osimertinib, which also targets the T790M resistance mutation, to either erlotinib or gefitinib.

Table.

EGFR, epidermal growth factor receptor; ORR, overall response rate; PFS, progression-free survival; TKI, tyrosine kinase inhibitor.

For additional commentary about this topic and others, visit www.gotoper.com to access additional resources from the 4th Annual Miami Lung Cancer Conference™, including downloadable slides from the meeting.

PER® Practice Pulse
Practice Pattern Questions
How often do you attend society oncology/hematology meetings? (ASCO, ASH, SABCS)
Practice Pattern Questions
What is the most significant barrier to implementing new information in your clinical practice?






Become a Member

Forgot Password?
Filter By